JPMorgan Chase & Co. Decreases Stake in Evolus, Inc. $EOLS

JPMorgan Chase & Co. decreased its holdings in Evolus, Inc. (NASDAQ:EOLS) by 35.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 446,311 shares of the company’s stock after selling 246,175 shares during the quarter. JPMorgan Chase & Co. owned about 0.69% of Evolus worth $2,740,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. State of Alaska Department of Revenue acquired a new position in shares of Evolus during the 3rd quarter worth $26,000. Wexford Capital LP acquired a new stake in shares of Evolus in the third quarter valued at about $37,000. Aquatic Capital Management LLC purchased a new stake in Evolus during the third quarter worth about $48,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Evolus during the third quarter worth about $62,000. Finally, Tower Research Capital LLC TRC grew its position in Evolus by 340.2% during the second quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock worth $68,000 after buying an additional 5,691 shares during the period. Institutional investors and hedge funds own 90.69% of the company’s stock.

Insider Buying and Selling at Evolus

In related news, insider David Moatazedi sold 116,720 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $4.89, for a total transaction of $570,760.80. Following the sale, the insider owned 618,369 shares of the company’s stock, valued at $3,023,824.41. This trade represents a 15.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rui Avelar sold 29,996 shares of Evolus stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $4.89, for a total value of $146,680.44. Following the sale, the insider owned 430,542 shares of the company’s stock, valued at approximately $2,105,350.38. This represents a 6.51% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 163,504 shares of company stock valued at $797,184 in the last three months. 5.90% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on EOLS shares. Stifel Nicolaus reduced their price target on shares of Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Tuesday, January 13th. BTIG Research restated a “buy” rating and issued a $13.00 price target on shares of Evolus in a report on Wednesday, March 4th. HC Wainwright dropped their price objective on Evolus from $20.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Evolus in a report on Wednesday, December 24th. Finally, Wall Street Zen lowered Evolus from a “buy” rating to a “hold” rating in a report on Sunday, March 15th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $16.00.

Evolus Price Performance

Shares of NASDAQ EOLS opened at $4.03 on Monday. The firm’s 50-day moving average is $4.60 and its two-hundred day moving average is $5.82. The company has a market capitalization of $262.19 million, a PE ratio of -4.98 and a beta of 1.00. Evolus, Inc. has a 12-month low of $3.86 and a 12-month high of $12.28.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported $0.00 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.09). The firm had revenue of $90.30 million for the quarter, compared to analyst estimates of $89.58 million. On average, analysts forecast that Evolus, Inc. will post -0.61 EPS for the current fiscal year.

Evolus Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.